ClinicalTrials.gg
RecruitingNCT07804316Updated Sep 4, 2026

Fostering Self-Empowerment in CKD Patients Through Food Choice Mapping

An observational study in CKD and Chronic Kidney Disease (Stages 3b-5), sponsored by Singapore Institute of Technology. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Singapore Institute of Technology · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
30
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Renal Insufficiency, Chronic with a site in Singapore — 5 open to participants now, 9 under way, 5 of them phase 3. Renal Insufficiency, Chronic · Singapore.

Started
2026
the only one that year
Observational
6 of 32
1 open now
Registered
32nd of 32
by date

Among the 32 studies in Renal Insufficiency, Chronic with a site in Singapore, this one is the only one that started in 2026, is one of 6 observational ones, and was the 32nd registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

5 of the 32 studies in Renal Insufficiency, Chronic with a site in Singapore are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency, Chronic with a site in Singapore, or all of them as a file.
02

Study summary

This project aims to develop mapping of food choices available for chronic kidney disease (CKD) patients when dining out in Singapore. Following the mapping, a mobile application will be developed based on renal dining out food map mobile application (RENDOFOMAP) and trialed on patients with CKD. The specific aims of the project include:

  1. Mapping out food choices suitable for patients with CKD when dining out in Singapore which will eventually be translated into a mobile application incorporating simple AI functionality.
  2. To evaluate the impact of using RENDOFOMAP on self-empowerment, quality of life, nutritional status, and serum biochemistry in patients with CKD.
  3. To evaluate the acceptability and user experience of RENDOFOMAP

Participants with CKD will use the newly developed mobile application to find out if there is improvement in self-empowerment, quality of life, nutritional status, and serum biochemistry.

Read the detailed description

Diet is integral in CKD management; however, it is not sustainable for patients in the long term if there is solely emphasis on food restrictions without providing knowledge on modifying food choices to allow enjoyment. Thus, a strategic nutritional education approach needs to be adopted to maximise cost-effectiveness.

Patients' self-empowerment is gaining recognition as a means to optimise hospital resource utilisation, reduce healthcare costs, and decrease patients' dependency on medical services. This is particularly relevant for patients with chronic kidney disease (CKD), who are required to adhere to a disease management regimen that often conflicts with their pre-diagnosis lives and priorities.

In recent years, mobile applications have emerged as a popular platform for delivering nutrition education programs. Research indicates that mobile applications designed to engage patients and promote self-management of CKD show promise in improving adherence to dietary restrictions related to sodium, potassium, phosphorus, protein, calories, and fluid intake. Some of these applications offer a range of features but will still need to be reviewed by dietitians during face-to-face consultations. This in-depth approach, while beneficial, may not fully optimise time efficiency for dietitians.

Thus, there is an impetus to create an improved mobile application for CKD nutritional management to allow patients to individualise food choices, on top of charting food intake in the form of food diary. Patients can be trained to use the application during dietetics session which can eventually help reduce time spent for each session thereby improving dietitians' workload.

The proposed application will also incorporate some preliminary Artificial Intelligence (AI) to offer personalised food choices for patients. This feature is expected to further enhance the user-friendliness and convenience of the application, thereby promoting its usage and empowerment among CKD patients.

03

Conditions studied

  • CKD
  • Chronic Kidney Disease (Stages 3b-5)

Keywords

  • artificial intelligence
  • nutrition app
  • renal nutrition
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited from inpatient and outpatient setting in a tertiary hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are fluent in English. This is necessary to ensure clear communication and understanding of study procedures and materials.
  • Adequate proficiency in using smartphone i.e. downloading app, taking photo, completing e-forms within the mobile applications. This is essential for participants to effectively use the mobile application being tested.
  • Diagnosed with CKD Stage 3B-5. This targets the specific patient population that the study aims to benefit.

Exclusion criteria

Exclusion Criteria:

  • Only fluent in languages other than English. This could hinder effective communication and understanding of the study.
  • Diagnosis of cognitive deficit or neurological disorder. These conditions could impair the ability to follow study procedures or provide reliable data.
  • Uncontrolled diabetes (>8.5%). This condition could introduce additional health risks and confound study results.
  • Recent hypoglycemic episodes. This could pose a safety risk during the study.
  • Newly initiated on dialysis or planning for dialysis within the next 6 months. These patients may have rapidly changing health conditions that could affect study outcomes.
  • Decompensated liver cirrhosis. This condition could complicate the interpretation of study results.
  • Pregnant and lactating. These conditions could introduce additional variables that affect study outcomes.
  • Inability to provide consent. This ensures that all participants can legally and ethically participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Interventions

  • OtherMobile application empowerment approach

    Participant will be provided access to the prototype mobile application known for this trial. Participants will be required to utilise the mobile application for 12 days (two 6-consecutive days, twice within 3 months) during a 3-month period. During the agreed dates, participant will need to take photos of their food intake and upload them onto the mobile application for evaluation.

06

What researchers measure

Primary outcomes

  1. Physical Health-Related Quality of Life

    Physical Health-Related Quality of Life At baseline and Week 12-16, physical health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The Physical Component Summary (PCS) score ranges from 5 to 20, with lower scores indicating better health-related quality of life and higher scores indicating poorer health-related quality of life.

    Time frame: Baseline to the end of study at 12-16 weeks

  2. Mental Health-Related Quality of Life

    At baseline and Week 12-16, mental health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12). The Mental Component Summary (MCS) score ranges from 12 to 45, with lower scores indicating better health-related quality of life and higher scores indicating poorer health-related quality of life.

    Time frame: Baseline to the end of study at 12-16 weeks

  3. Modified Nutrition-related Empowerment Scale

    At baseline and Week 12-16, nutrition-related empowerment will be assessed using a modified version of the Korean Health Empowerment Scale (K-HES). The scale consists of 8 items scored from 1 (Strongly Disagree) to 5 (Strongly Agree). Item scores are summed to generate a total score ranging from 8 to 40, with higher scores indicating greater nutrition-related empowerment and self-management capacity.

    Time frame: Baseline to the end of study at 12-16 weeks

  4. Ease of Adherence to Diet Plan When Eating Out

    Participants will rate the ease of adhering to their prescribed diet plan when eating out using a 5-point scale ranging from 1 (very difficult) to 5 (very easy). Higher scores indicate greater ease of dietary adherence.

    Time frame: Baseline to the end of study at 12-16 weeks

  5. Food Diary Completion Rate

    Participant engagement with the nEAT mobile application will be assessed by the proportion of scheduled food diary entries completed during the intervention period. Food diary completion rate (%) = (Number of completed food diary entries ÷ Total number of scheduled food diary entries) × 100. A food diary entry is considered completed when the participant records the required dietary information for the scheduled eating occasion within the nEAT mobile application

    Time frame: Baseline to the end of study at 12-16 weeks

Secondary outcomes

  1. Body Weight Change

    Body weight will be measured at baseline and Week 12-16 using a calibrated weighing scale. Weight will be reported in kilograms (kg). Body weight change (kg) = Body weight at Week 12-16 - Body weight at baseline. Negative values indicate a reduction in body weight (weight loss), positive values indicate an increase in body weight (weight gain), and a value of 0 indicates no change in body weight.

    Time frame: Baseline to the end of study at 12-16 weeks

  2. Percentage Weight Change

    Percentage weight change over the preceding 6 months will be calculated from self-reported and/or documented body weight records. Weight change will be reported as a percentage (%).

    Time frame: Baseline to the end of study at 12-16 weeks

  3. Body Mass Index (BMI)

    Body mass index (BMI) will be calculated as weight (kg) divided by height squared (m²), expressed as kg/m². BMI Asian categories are Underweight: Less than 18.5 kg/m² Normal range: 18.5 to 22.9 kg/m² Overweight (At risk): 23.0 to 24.9 kg/m² Obese (Class I): 25.0 to 29.9 kg/m² Obese (Class II): ≥ 30.0 kg/m²

    Time frame: Baseline to the end of study at 12-16 weeks

  4. Nutritional Status [Subjective Global Assessment (SGA)}

    Nutritional status will be assessed using the Subjective Global Assessment (SGA), incorporating recent weight loss, dietary intake, gastrointestinal symptoms, functional status, muscle wasting, fat wasting, oedema, and overall nutritional status. Overall subjective scores range from 1 to 7, where 1-2 indicates severely malnourished, 3-5 moderately malnourished and 6-7 indicates being well nourished.

    Time frame: Baseline to the end of study at 12-16 weeks

  5. Ease of Adherence to Diet Plan When Eating at Home

    Participants will rate the ease of adhering to their prescribed diet plan when eating at home before and after using nEAT mobile application using a 5-point scale ranging from 1 (very difficult) to 5 (very easy). Higher scores indicate greater ease of dietary adherence.

    Time frame: Baseline to the end of study at 12-16 weeks

  6. Energy Intake Relative to Estimated Requirements

    Energy intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual energy requirements will be estimated using the Harris-Benedict equation based on age (years), weight (kg), and height (cm), and used to establish personalized energy targets. Energy intake will be expressed as a percentage of the estimated energy requirement (%), calculated as actual energy intake divided by estimated energy requirement × 100. Values closer to 100% indicate greater adherence to prescribed energy targets.

    Time frame: Baseline to the end of study at 12-16 weeks

  7. Protein Intake Relative to Estimated Requirements

    Protein intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual actual protein requirements will be estimated using the factor 0.8g/kg x weight (kg), and used to establish personalized energy targets. Protein intake will be expressed as a percentage of the estimated protein requirement (%), calculated as actual protein intake divided by estimated protein requirement × 100. Values closer to 100% indicate greater adherence to prescribed energy targets.

    Time frame: Baseline to the end of study at 12-16 weeks

  8. Sodium Intake Relative to Estimated Requirements

    Sodium intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual sodium allowance will limited to 2000mg per person . Energy intake will be expressed as a percentage of the sodium allowance (%), calculated as actual sodium intake divided by estimated sodium allowance × 100. Values closer to 100% indicate greater adherence to prescribed sodium targets.

    Time frame: Baseline to the end of study at 12-16 weeks

  9. Phosphorus Intake Relative to Estimated Requirements

    Phosphorus intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual phosphorus allowances will be personalised and estimated proportionally to protein intake. Phosphorus intake will be expressed as a percentage of the estimated phosphorus allowance (%), calculated as actual phosphorus intake divided by estimated phosphorus allowance × 100. Values closer to 100% indicate greater adherence to prescribed phosphorus targets.

    Time frame: Baseline to the end of study at 12-16 weeks

  10. Potassium Intake Relative to Estimated Requirements

    Potassium intake will be assessed using 24-hour dietary recalls completed at baseline and end of study at 12-16 weeks. Individual potassium allowance will calculated at 39mg/kg per person, however, will be personalised based on the chronic kidney stage and serum biochemistry potassium. Potassium intake will be expressed as a percentage of the individualised potassium allowance (%), calculated as actual sodium intake divided by estimated potassium allowance × 100. Values closer to 100% indicate greater adherence to prescribed potassium targets.

    Time frame: Baseline to the end of study at 12-16 weeks

Other outcomes

  1. Change in Estimated Glomerular Filtration Rate (eGFR)

    Estimated glomerular filtration rate (eGFR), a laboratory-based measure of kidney function, will be assessed at baseline and at the end of the study (12-16 weeks). eGFR will be reported in millilitres per minute per 1.73 m² (mL/min/1.73 m²). The outcome measure will be the change in eGFR from baseline to study completion. Lower eGFR values compared to baseline indicate poorer kidney function.

    Time frame: Baseline to the end of study at 12-16 weeks

  2. Change in Serum Creatinine

    Renal function will be assessed by measuring serum creatinine concentration and reported in micromoles per litre (µmol/L) at baseline and end of study at 12-16 weeks. Higher values from baseline indicate poorer or declining kidney function. Reference value, male: 54 - 101; female: 37 - 75 µmol/L

    Time frame: Baseline to the end of study at 12-16 weeks

  3. Serum Potassium Concentration

    Serum potassium concentration will be measured and reported in millimoles per litre (mmol/L). Reference value: 3.6 - 5.0 mmol/L. Higher value from baseline signifies worsening of hyperkalemia

    Time frame: Baseline to the end of study at 12-16 weeks

  4. Change in Serum Albumin

    Nutritional status will be assessed using serum albumin concentration and reported in grams per litre (g/L) at baseline and end of study at 12-16 weeks. Higher values indicate better nutritional status compared to baseline. Reference value: 40 - 51 g/L

    Time frame: Baseline to the end of study at 12-16 weeks

  5. CKD-Related Hospital Admissions Compared Against Compliance to 24-hour Diet Recall

    Hospital admissions related to chronic kidney disease or its complications occurring during the study period will be recorded and reported as the total number of admissions in comparison to the stratification of24-hour Diet Recall.

    Time frame: End of study at 12-16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2026
First posted
Sep 4, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Jan 16, 2027
CompletionEst.
Aug 16, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07804316
Lead sponsor
Singapore Institute of Technology
Collaborators
Singapore General Hospital, Sengkang General Hospital
Responsible party
Gary Tung Lin Chiah (Senior Lecturer, Singapore Institute of Technology) — Principal investigator
First posted
Sep 4, 2026
Start date
Apr 15, 2026
Primary completion
Jan 16, 2027 (estimated)
Completion
Aug 16, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Gary Tung Lin Chiah, MSc, BSc, RD
Contact
gary.chiah@singaporetech.edu.sg
+6565925769
Gary Tung Lin Chiah, MSc, BSc, RD
principal investigator · Singapore Institute of Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion